Suppr超能文献

利妥昔单抗治疗儿童难治性抗 NMDAR 脑炎的药学监护:1 例报告。

Pharmaceutical care of rituximab in the treatment of children with refractory anti-NMDAR encephalitis: A case report.

机构信息

Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.

School of Pharmacy, Shandong First Medical University, Jinan, China.

出版信息

Medicine (Baltimore). 2023 Feb 3;102(5):e32843. doi: 10.1097/MD.0000000000032843.

Abstract

RATIONALE

Anti- N -methyl- d -aspartate receptor (NMDAR) encephalitis is a rare disease of nervous system, which is mediated by autoimmune mechanisms. The treatment of anti-NMDAR encephalitis includes Immunotherapy, symptomatic and supportive treatment for seizures and psychiatric symptoms. There are many kinds of drugs, so drug treatment management and pharmaceutical care for children are particularly important. At present, there are few reports on pharmaceutical care for children with this disease. Clinical pharmacists participated in the pharmaceutical care of a child with refractory anti-NMDAR encephalitis treated with rituximab, conducted drug treatment management on the dosage, administration method, complications and other aspects of off-label use of rituximab, combined with the children's clinical manifestations, inflammatory indicators, pathogenic detection, blood concentration, liver and kidney functions, drug interactions and other factors. The treatment plan of anti-infective drugs shall be adjusted, and attention shall be paid to whether there are adverse reactions during the treatment.

PATIENT CONCERNS

A 4-year-old girl presented with epileptic seizure, intermittent recurrent fever, high inflammatory markers, abnormal psychiatric function/cognitive impairment, language disorder, consciousness disturbance, and movement disorder/involuntary movement.

DIAGNOSIS

Refractory anti-NMDAR encephalitis.

INTERVENTIONS

The patient was given first-line (3 rounds of methylprednisolone pulse therapy and gamma globulin) and second-line (rituximab) immunotherapy. On the advice of a clinical pharmacist, the patient wasn't given Advanced antibacterial agents (voriconazole, vancomycin) therapy. On the 41st day of admission, the patient's temperature and inflammatory indicators were normal, CD19 + B cells were reduced to 0.

OUTCOMES

The patient consciousness level, cognition and orientation were gradually improved, mental disorder was improved, involuntary movement was obviously controlled, no seizure occurred again, and the patient was discharged with stable condition.

LESSONS

Clinical pharmacists ensure the safety, effectiveness and economy of patients' medication by carrying out the whole process of individualized drug treatment management and care for patients.

摘要

背景

抗 N -甲基- d -天冬氨酸受体(NMDAR)脑炎是一种罕见的神经系统疾病,由自身免疫机制介导。抗 NMDAR 脑炎的治疗包括免疫治疗、对症和支持治疗癫痫发作和精神症状。药物种类繁多,因此儿童的药物治疗管理和药学护理尤为重要。目前,关于该疾病儿童药学护理的报道较少。临床药师参与了一例利妥昔单抗治疗难治性抗 NMDAR 脑炎患儿的药学监护,对利妥昔单抗的适应证外使用剂量、给药方法、并发症等方面进行了药物治疗管理,结合患儿的临床表现、炎症指标、病原学检测、血药浓度、肝肾功能、药物相互作用等因素,调整抗感染药物治疗方案,注意治疗过程中是否有不良反应。

患者关注

一名 4 岁女孩出现癫痫发作、间歇性反复发热、炎症标志物升高、精神/认知功能异常、语言障碍、意识障碍、运动障碍/不自主运动。

诊断

难治性抗 NMDAR 脑炎。

干预措施

患儿给予一线(3 轮甲泼尼龙脉冲治疗和丙种球蛋白)和二线(利妥昔单抗)免疫治疗。临床药师建议患儿不给予高级抗菌药物(伏立康唑、万古霉素)治疗。入院第 41 天,患者体温和炎症指标正常,CD19 + B 细胞降至 0。

结果

患者意识水平、认知和定向逐渐改善,精神障碍改善,不自主运动明显控制,无癫痫发作,病情稳定出院。

经验教训

临床药师通过对患者进行个体化药物治疗管理和护理的全过程,确保了患者用药的安全性、有效性和经济性。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验